This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer for ProfessionalsYour Resource Portal

Finding a consensus on utilising triplet therapy in mHSPC patients

Discussion from an expert panel at P3 Prostate Cancer Forum 2025.

P3 background - Article

Finding a consensus on utilising triplet therapy in metastatic hormone sensitive cancer (mHSPC) patients, an expert panel discussion.

In this thought-provoking discussion at P3 Prostate Cancer Forum 2025, esteemed panellists engaged with the audience on key clinical controversies within metastatic prostate cancer treatment.

They tackle pivotal questions, such as whether triplet therapy (androgen deprivation therapy (ADT) plus docetaxel plus androgen receptor pathway inhibitor (ARPI)) should be recommended for patients with metachronous low-burden mHSPC, and which ARPI is preferable for those with a history of cognitive impairment, fatigue, or fall?

By examining these insights, healthcare professionals can gain a deeper understanding of how the consensus statements can be applied to enhance clinical practice and improve patient outcomes.
 

Expert consensus panel discussion

NUBEQA  (darolutamide) Prescribing Information

Meet the Speakers

  • Speakers:

    Professor Noel Clarke, Consultant Urological Surgeon, The Christie and Salford Royal Hospitals Manchester

     

    Chairs:

    Mr William Cross, Consultant Urologist, Leeds Teaching Hospitals NHS Trust

    Professor Alison Birtle, Consultant Oncologist, Lancashire Teaching Hospitals NHS Trust

    Professor Amit Bahl, Consultant in Clinical Oncology, Bristol Cancer Institute

    Professor Fred Saad, Urologist & Oncologist, The University of Montreal Hospital Center

Resources to support prostate cancer patients
A focus on drug-to-drug interactions, managing risk and navigating around psychosexual health.
PP-NUB-GB-2385, June 2025
Exploring the mHSPC Patient Journey
Join experts for evidence-based treatment strategies on the application of triple therapy in mHSPC.
PP-NUB-GB-2382, June 2025
P3 Prostate Cancer Forum 2025
Join us as we recap the P3 Prostate Cancer Forum held on May 16-17, 2025.
PP-NUB-GB-2381, June 2025

PP-NUB-GB-2383, June 2025